Metilfenidat
| |||
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| metil fenil(piperidin-2-il)acetat | |||
| Klinički podaci | |||
| Robne marke | Concerta, Methylin, Ritalin, Equasym XL | ||
| AHFS/Drugs.com | Monografija | ||
| MedlinePlus | a682188 | ||
| Identifikatori | |||
| CAS broj | 113-45-1 | ||
| ATC kod | N06BA04 | ||
| PubChem[1][2] | 4158 | ||
| DrugBank | DB00422 | ||
| ChemSpider[3] | 4015 | ||
| UNII | 207ZZ9QZ49 
| ||
| KEGG[4] | D04999
| ||
| ChEBI | CHEBI:6887
| ||
| ChEMBL[5] | CHEMBL796
| ||
| Hemijski podaci | |||
| Formula | C14H19NO2 | ||
| Mol. masa | 233,30 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Fizički podaci | |||
| Tačka topljenja | 214 °C (417 °F) | ||
| Farmakokinetički podaci | |||
| Bioraspoloživost | ~30% (opseg: 11–52%) | ||
| Vezivanje za proteine plazme | 10-33% | ||
| Metabolizam | Hepatički (80%) | ||
| Poluvreme eliminacije | 3-4 sata (d-enantiomer), 1-3 sata (l-enantiomer) | ||
| Izlučivanje | Urin (90%) | ||
| Farmakoinformacioni podaci | |||
| Licenca | |||
| Trudnoća | B3(AU) C(US) | ||
| Pravni status | Droga (S8) (AU) Schedule III (CA) ? (UK) Schedule II (SAD) | ||
| Opojna droga | Moderate | ||
| Način primene | Oralno, transdermalno | ||
Metilfenidat (Concerta, Methylin, Ritalin, Equasym XL) je psihostimulišući lek i supstituisani fenetilamin koji je odobren tretman hiperkinetičkog poremećaja (ADHD), posturalnog ortostatskog tahikardnog sindroma i narkolepsije. Originalni patent je posedovalo preduzeće CIBA. FDA je odobrila ovaj lek 1955. za tretiranje hiperaktivnosti. Propisivan je od početka 1960-tih. Nivo proskripcija je znatno porastao tokom 1990-tih kad je ADHD dijagnoza postala šire prihvaćena.[6][7]
Reference
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ When Was Ritalin Invented?, citing Lawrence Diller: "Running on Ritalin", 1999
- ↑ Lange, K.W. et al.: The history of attention deficit hyperactivity disorder. In: Attention Deficit Hyperactivity Disorders, 2(4):241-55. doi: 10.1007/s12402-010-0045-8.
Literatura
- Gardiner Harris (3. 2. 2012.). „F.D.A. Finds Short Supply of Attention Deficit Drugs”. The New York Times. Arhivirano iz originala na datum 2012-02-03. Pristupljeno 3. 2. 2012. »(Archived by WebCite® at [1])«
- L. Alan Sroufe (28. 1. 2012.). „Ritalin Gone Wrong - Opinion - Children\'s A.D.D.Drugs Don\'t Work Long-Term”. The New York Times. Arhivirano iz originala na datum 2012-02-03. Pristupljeno 3. 2. 2012. »(Archived by WebCite® at [2])«
- Lakhan SE, Hagger-Johnson GE (2007). „The impact of prescribed psychotropics on youth”. Clin Pract Epidemol Ment Health 3 (1): 21. DOI:10.1186/1745-0179-3-21. PMC 2100041. PMID 17949504.
- Drug Enforcement Administration, Greene, S.H., Response to CHADD petition concerning Ritalin, 1995, August 7. Washington, DC: DEA, U.S. Department of Justice.
- New Research Helps Explain Ritalin's Low Abuse Potential When Taken As Prescribed – 09/29/1998 Arhivirano 2010-05-28 na Wayback Machine-u. Nih.gov. Retrieved on 2011-04-30.
- Weinberg WA, Brumback RA (1992). „The myth of attention deficit-hyperactivity disorder: symptoms resulting from multiple causes”. J. Child Neurol. 7 (4): 431–45; discussion 446–61. DOI:10.1177/088307389200700420. PMID 1469255.
- Presenters: Joan Hamburg and Dr. Harold Koplewicz (3. 2. 2012.). "Are we over medicating our kids? Speaking with Dr. Harold Koplewicz of @ChildMindDotOrg". Joan Hamburg Show (Radio). 1:11 into the complete two part show - 2 minutes in. WOR Radio Network. WOR. Archived from the original on 2012-12-03. Retrieved 2014-04-05.
{cite episode}: Check date values in:|airdate=(help); External link in|transcripturl=|city=ignored (|location=suggested) (help); Unknown parameter|transcripturl=ignored (|transcript-url=suggested) (help) „Archive copy”. Arhivirano iz originala na datum 2012-12-03. Pristupljeno 2014-04-05.
</ref>
